mental healthcare

President Trump is fast-tracking research into psychedelics as mental healthcare treatments, creating new market opportunities and regulatory pathways. This policy shift opens pharmaceutical investment opportunities while introducing regulatory uncertainties for companies developing psychedelic therapies.